The rostral ventrolateral medulla (RVLM) is the primary sympathetic vasomotor center in the brainstem and contains C1 adrenergic neurons that are essential for maintaining baseline blood pressure and sympathetic tone. These neurons project directly to sympathetic preganglionic neurons in the intermediolateral cell column of the spinal cord, making them the final common pathway for supraspinal sympathetic control. [1]
The RVLM receives input from the nucleus tractus solitarius (NTS), the hypothalamic pressor area, and higher cortical regions, integrating cardiovascular, respiratory, and emotional information to generate appropriate sympathetic responses. Dysfunction in RVLM neurons contributes to hypertension, autonomic failure in multiple system atrophy (MSA), and sleep-related breathing disorders. [2]
| Property | Value | [3]
|----------|-------| [4]
| Category | Brainstem Autonomic Nervous System | [5]
| Location | Rostral ventrolateral medulla, rostral to the obex | [6]
| Cell Types | Sympathetic premotor (C1 adrenergic) |
| Primary Neurotransmitter | Glutamate, Adrenaline |
| Key Markers | VGLUT2, TH, C1 adrenergic neurons, Phox2b |
| Projection Target | Intermediolateral cell column (IML), spinal cord |
| Afferent Inputs | NTS, paraventricular nucleus, hypothalamus |
The RVLM is the primary determinant of sympathetic vasomotor tone:
RVLM neurons control:
The RVLM integrates multiple inputs:
The RVLM is located in the ventrolateral medulla oblongata, approximately 2-4 mm rostral to the obex. The region contains:
RVLM neurons project to:
| Transmitter | Role |
|---|---|
| Glutamate | Main excitatory transmitter to IML |
| Adrenaline (C1) | Modulatory, enhances sympathetic tone |
| Substance P | Co-transmitter in some neurons |
| Neuropeptide Y | Inhibits baroreceptor reflex |
RVLM hyperactivity contributes to essential hypertension:
MSA involves:
RVLM dysfunction in OSA:
PD can involve autonomic dysfunction:
The C1 neurons in the RVLM are unique:
In hypertension:
| Drug Class | RVLM Mechanism |
|---|---|
| Beta-blockers | Reduce central sympathetic output |
| Alpha-2 agonists | Inhibit RVLM firing |
| Centrally acting agents | Clonidine, methyldopa |
| ACE inhibitors | Reduce angiotensin II in RVLM |
Experimental approaches:
The study of Rostral Ventrolateral Medulla Sympathetic Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Dampney RA. Functional organization of central pathways regulating the cardiovascular system. Physiol Rev. 1994. ↩︎
Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci. 2006. ↩︎
Schreihofer AM, Sved AF. Use of glutamate antagonists in the study of the regulation of blood pressure. Clin Exp Pharmacol Physiol. 1996. ↩︎
Low PA, et al. Autonomic nervous system disorders. Lancet. 2005. ↩︎
Somogyi P, et al. Adrenergic neurons in the rostral ventrolateral medulla. Prog Brain Res. 1996. ↩︎
Javaheri S, et al. Sleep apnea and cardiovascular disease. Circulation. 2008. ↩︎